https://invivo.partners/2019/03/29/invivo-se-estrena-con-un-fondo-biomedico-de-40-millones/ 2020-03-09T14:59:43+00:00 https://invivo.partners/2019/03/29/invivo-invertira-40-millones-en-el-sector-biomedico/ 2020-03-09T14:59:51+00:00 https://invivo.partners/2019/03/29/invivo-capital-abre-su-fondo-biomedico-con-40-millones-de-euros/ 2020-03-09T15:00:03+00:00 https://invivo.partners/2019/03/29/invivo-se-estrena-con-un-fondo-biomedico-de-40-millones/ 2020-03-09T15:16:57+00:00 https://invivo.partners/2019/03/29/invivo-invertira-40-millones-en-el-sector-biomedico/ 2020-03-09T15:17:15+00:00 https://invivo.partners/2019/03/29/invivo-capital-abre-su-fondo-biomedico-con-40-millones-de-euros/ 2020-03-09T15:17:27+00:00 https://invivo.partners/2020/04/14/barcelona-based-synthetic-biology-company-secures-two-million-euro-investment/ 2020-04-14T12:49:53+00:00 https://invivo.partners/2020/04/15/pulmobiotics-consigue-dos-millones-para-su-inhalador/ 2020-04-15T11:28:59+00:00 https://invivo.partners/2020/04/14/barcelona-based-synthetic-biology-company-secures-two-million-euro-investment/ 2020-05-25T21:37:14+00:00 https://invivo.partners/2020/05/26/a-new-cancer-immune-therapy-spin-off-of-hospital-clinic-idibaps-barcelona-secures-a-1-5-million-euro-investment-from-invivo-ventures/ 2020-05-26T14:19:59+00:00 https://invivo.partners/2020/05/26/invivo-ventures-invierte-15-millones-en-gyala-therapeutics/ 2020-05-26T14:23:47+00:00 https://invivo.partners/2020/05/26/invivo-ventures-invierte-e15-millones-en-gyala-therapeutics/ 2020-05-26T14:27:19+00:00 https://invivo.partners/2020/05/26/gyala-therapeutics-capta-15-millones-de-euros-de-invivo-ventures/ 2020-05-26T14:33:03+00:00 https://invivo.partners/2020/05/26/a-new-cancer-immune-therapy-spin-off-of-hospital-clinic-idibaps-barcelona-secures-a-1-5-million-euro-investment-from-invivo-ventures/ 2020-05-26T14:45:25+00:00 https://invivo.partners/2020/05/26/gyala-therapeutics-capta-15-millones-de-euros-de-invivo-ventures/ 2020-05-26T14:45:34+00:00 https://invivo.partners/2020/05/26/invivo-ventures-invierte-15-millones-en-gyala-therapeutics/ 2020-05-26T14:45:46+00:00 https://invivo.partners/2020/05/26/invivo-ventures-invierte-e15-millones-en-gyala-therapeutics/ 2020-05-26T14:45:57+00:00 https://invivo.partners/2020/04/15/pulmobiotics-consigue-dos-millones-para-su-inhalador/ 2020-05-26T14:46:21+00:00 https://invivo.partners/2020/04/15/invivo-ventures-invierte-dos-millones-en-la-biotecnologica-pulmobiotics/ 2020-05-26T14:46:28+00:00 https://invivo.partners/2020/04/15/invivo-ventures-invierte-dos-millones-en-la-biotecnologica-pulmobiotics/ 2020-05-26T14:46:28+00:00 https://invivo.partners/2020/04/14/barcelona-based-synthetic-biology-company-secures-two-million-euro-investment/ 2020-05-26T14:46:38+00:00 https://invivo.partners/2020/04/14/invivo-ventures-impulsa-pulmobiotics-con-una-inyeccion-inicial-de-dos-millones-de-euros/ 2020-05-26T14:46:46+00:00 https://invivo.partners/2020/04/14/invivo-ventures-impulsa-pulmobiotics-con-una-inyeccion-inicial-de-dos-millones-de-euros/ 2020-05-26T14:46:46+00:00 https://invivo.partners/2019/03/29/invivo-se-estrena-con-un-fondo-biomedico-de-40-millones/ 2020-05-26T14:47:40+00:00 https://invivo.partners/2019/03/29/invivo-invertira-40-millones-en-el-sector-biomedico/ 2020-05-26T14:47:46+00:00 https://invivo.partners/2019/03/29/invivo-capital-abre-su-fondo-biomedico-con-40-millones-de-euros/ 2020-05-26T14:47:53+00:00 https://invivo.partners/2020/07/13/telum-therapeutics-raises-e-4-1-million-in-its-first-round-of-financing-to-advance-the-development-of-new-synthetic-biology-based-therapies-for-the-treatment-of-infectious-diseases-caused-by-multi-res/ 2020-07-13T14:38:53+00:00 https://invivo.partners/2020/07/13/telum-therapeutics-raises-e-4-1-million-in-its-first-round-of-financing-to-advance-the-development-of-new-synthetic-biology-based-therapies-for-the-treatment-of-infectious-diseases-caused-by-multi-res/ 2020-07-13T14:38:55+00:00 https://invivo.partners/2020/07/13/telum-therapeutics-raises-e-4-1-million-in-its-first-round-of-financing-to-advance-the-development-of-new-synthetic-biology-based-therapies-for-the-treatment-of-infectious-diseases-caused-by-multi-res/ 2020-07-13T14:41:38+00:00 https://invivo.partners/2020/05/26/invivo-ventures-invierte-e15-millones-en-gyala-therapeutics/ 2020-07-13T14:47:05+00:00 https://invivo.partners/2020/05/26/invivo-ventures-invierte-15-millones-en-gyala-therapeutics/ 2020-07-13T14:47:14+00:00 https://invivo.partners/2020/05/26/gyala-therapeutics-capta-15-millones-de-euros-de-invivo-ventures/ 2020-07-13T14:47:22+00:00 https://invivo.partners/2020/05/26/a-new-cancer-immune-therapy-spin-off-of-hospital-clinic-idibaps-barcelona-secures-a-1-5-million-euro-investment-from-invivo-ventures/ 2020-07-13T14:47:45+00:00 https://invivo.partners/2020/04/15/invivo-ventures-invierte-dos-millones-en-la-biotecnologica-pulmobiotics/ 2020-07-13T14:47:56+00:00 https://invivo.partners/2020/04/15/pulmobiotics-consigue-dos-millones-para-su-inhalador/ 2020-07-13T14:48:02+00:00 https://invivo.partners/2020/04/14/invivo-ventures-impulsa-pulmobiotics-con-una-inyeccion-inicial-de-dos-millones-de-euros/ 2020-07-13T14:48:09+00:00 https://invivo.partners/2020/07/13/telum-therapeutics-cierra-una-ronda-de-41-millones-liderada-por-invivo-ventures/ 2020-07-13T15:30:40+00:00 https://invivo.partners/2020/07/13/telum-therapeutics-cierra-una-ronda-de-41-millones-liderada-por-invivo-ventures/ 2020-07-13T15:30:40+00:00 https://invivo.partners/2020/07/13/telum-therapeutics-cierra-una-ronda-de-41-millones-liderada-por-invivo-ventures/ 2020-07-13T15:30:41+00:00 https://invivo.partners/2020/07/20/invivo-ventures-cdti-innvierte-y-la-fundacion-josep-carreras-cierran-una-ronda-de-financiacion-de-3-050-000e-en-onechain-immunotherapeutics/ 2020-07-20T09:02:37+00:00 https://invivo.partners/2020/07/20/invivo-ventures-cdti-innvierte-y-la-fundacion-josep-carreras-cierran-una-ronda-de-financiacion-de-3-050-000e-en-onechain-immunotherapeutics/ 2020-07-20T09:02:37+00:00 https://invivo.partners/2020/07/20/invivo-ventures-cdti-innvierte-y-la-fundacion-josep-carreras-cierran-una-ronda-de-financiacion-de-3-050-000e-en-onechain-immunotherapeutics/ 2020-07-20T09:02:37+00:00 https://invivo.partners/2020/07/20/invivo-ventures-cdti-innvierte-y-la-fundacion-josep-carreras-cierran-una-ronda-de-e305-millones-en-onechain-immunotherapeutics/ 2020-07-20T09:07:04+00:00 https://invivo.partners/2020/07/20/invivo-ventures-cdti-innvierte-y-la-fundacion-josep-carreras-cierran-una-ronda-de-e305-millones-en-onechain-immunotherapeutics/ 2020-07-20T09:07:05+00:00 https://invivo.partners/2020/07/20/invivo-ventures-cdti-innvierte-y-la-fundacion-josep-carreras-cierran-una-ronda-de-e305-millones-en-onechain-immunotherapeutics/ 2020-07-20T09:07:05+00:00 https://invivo.partners/2020/07/20/the-josep-carreras-institute-creates-a-spin-off-to-develop-therapies-for-leukaemia-based-on-car-t/ 2020-07-23T08:21:13+00:00 https://invivo.partners/2020/07/20/the-josep-carreras-institute-creates-a-spin-off-to-develop-therapies-for-leukaemia-based-on-car-t/ 2020-07-23T08:25:30+00:00 https://invivo.partners/2020/07/20/the-josep-carreras-institute-creates-a-spin-off-to-develop-therapies-for-leukaemia-based-on-car-t/ 2020-07-23T08:29:05+00:00 https://invivo.partners/2020/07/23/arthex-secures-e4-25m-from-invivo-ventures-and-advent-france-biotechnology/ 2020-07-23T11:43:33+00:00 https://invivo.partners/2020/07/23/arthex-secures-e4-25m-from-invivo-ventures-and-advent-france-biotechnology/ 2020-07-23T11:43:33+00:00 https://invivo.partners/2020/07/23/arthex-secures-e4-25m-from-invivo-ventures-and-advent-france-biotechnology/ 2020-07-23T11:45:50+00:00 https://invivo.partners/2020/12/01/cientificas-del-cnio-y-de-la-universidad-autonoma-de-barcelona-crean-una-spin-off-para-desarrollar-el-primer-tratamiento-contra-la-fibrosis-pulmonar-basado-en-terapia-genica/ 2020-12-01T12:31:19+00:00 https://invivo.partners/wp-content/uploads/2020/12/foto1.jpg https://invivo.partners/wp-content/uploads/2020/12/foto2.jpg https://invivo.partners/2020/12/01/cientificas-del-cnio-y-de-la-universidad-autonoma-de-barcelona-crean-una-spin-off-para-desarrollar-el-primer-tratamiento-contra-la-fibrosis-pulmonar-basado-en-terapia-genica/ 2020-12-02T08:01:04+00:00 https://invivo.partners/wp-content/uploads/2020/12/foto1.jpg https://invivo.partners/wp-content/uploads/2020/12/foto2.jpg https://invivo.partners/2020/12/01/cientificas-del-cnio-y-de-la-universidad-autonoma-de-barcelona-crean-una-spin-off-para-desarrollar-el-primer-tratamiento-contra-la-fibrosis-pulmonar-basado-en-terapia-genica/ 2020-12-03T11:18:39+00:00 https://invivo.partners/wp-content/uploads/2020/12/foto1.jpg https://invivo.partners/wp-content/uploads/2020/12/foto2.jpg https://invivo.partners/2020/12/16/minoryxs-clinical-candidate-leriglitazone-shows-clinical-benefit-in-a-proof-of-concept-phase-2-study-in-friedreichs-ataxia/ 2020-12-16T08:56:32+00:00 https://invivo.partners/2020/12/16/minoryxs-clinical-candidate-leriglitazone-shows-clinical-benefit-in-a-proof-of-concept-phase-2-study-in-friedreichs-ataxia/ 2020-12-16T08:56:32+00:00 https://invivo.partners/2020/12/16/minoryxs-clinical-candidate-leriglitazone-shows-clinical-benefit-in-a-proof-of-concept-phase-2-study-in-friedreichs-ataxia/ 2020-12-16T08:56:33+00:00 https://invivo.partners/2020/12/16/peptomyc-capta-114-millones-para-iniciar-un-ensayo-clinico-en-cancer/ 2020-12-16T09:03:46+00:00 https://invivo.partners/2020/12/16/peptomyc-capta-114-millones-para-iniciar-un-ensayo-clinico-en-cancer/ 2020-12-16T09:03:46+00:00 https://invivo.partners/2020/12/16/peptomyc-capta-114-millones-para-iniciar-un-ensayo-clinico-en-cancer/ 2020-12-16T09:03:47+00:00 https://invivo.partners/2021/03/12/lajuntament-de-barcelona-ha-seleccionat-invivo-ventures-fcr-junt-amb-altres-5-fons-de-capital-risc-privats-per-participar-en-la-iniciativa-barcelona-accelera/ 2021-03-12T08:31:59+00:00 https://invivo.partners/2021/03/12/lajuntament-de-barcelona-ha-seleccionat-invivo-ventures-fcr-junt-amb-altres-5-fons-de-capital-risc-privats-per-participar-en-la-iniciativa-barcelona-accelera/ 2021-03-12T08:31:59+00:00 https://invivo.partners/2021/03/12/lajuntament-de-barcelona-ha-seleccionat-invivo-ventures-fcr-junt-amb-altres-5-fons-de-capital-risc-privats-per-participar-en-la-iniciativa-barcelona-accelera/ 2021-03-12T08:32:01+00:00 https://invivo.partners/2021/12/02/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures/ 2021-12-02T10:38:48+00:00 https://invivo.partners/2021/12/02/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures/ 2021-12-02T10:40:40+00:00 https://invivo.partners/2021/12/02/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures/ 2021-12-02T10:42:41+00:00 https://invivo.partners/2021/12/03/la-start-up-integra-tx-capta-45-millones-de-advent-invivo-y-takeda/ 2021-12-03T14:12:53+00:00 https://invivo.partners/2021/12/03/la-start-up-integra-tx-capta-45-millones-de-advent-invivo-y-takeda/ 2021-12-03T14:25:17+00:00 https://invivo.partners/2021/12/03/la-start-up-integra-tx-capta-45-millones-de-advent-invivo-y-takeda/ 2021-12-03T14:36:16+00:00 https://invivo.partners/2021/12/09/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula/ 2021-12-09T10:28:39+00:00 https://invivo.partners/2021/12/09/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula/ 2021-12-09T10:31:21+00:00 https://invivo.partners/2021/12/09/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula/ 2021-12-09T10:36:40+00:00 https://invivo.partners/2022/03/30/integra-therapeutics-completes-the-e6-million-seed-round-with-the-addition-of-columbus-venture-partners/ 2022-03-30T08:12:37+00:00 https://invivo.partners/2022/03/30/integra-therapeutics-completes-the-e6-million-seed-round-with-the-addition-of-columbus-venture-partners/ 2022-03-30T08:15:37+00:00 https://invivo.partners/2022/03/30/integra-therapeutics-completes-the-e6-million-seed-round-with-the-addition-of-columbus-venture-partners/ 2022-03-30T08:24:26+00:00 https://invivo.partners/2022/04/25/job-opportunity-we-are-looking-for-controller-candidates-if-you-are-interested-please-apply/ 2022-04-25T10:00:32+00:00 https://invivo.partners/2022/04/25/job-opportunity-we-are-looking-for-controller-candidates-if-you-are-interested-please-apply/ 2022-04-25T10:03:20+00:00 https://invivo.partners/2022/04/25/job-opportunity-we-are-looking-for-controller-candidates-if-you-are-interested-please-apply/ 2022-04-25T10:04:01+00:00 https://invivo.partners/2022/06/10/job-opportunity-were-seeking-candidates-with-a-strong-scientific-background-to-join-our-internship-opportunity-if-youre-interested-in-learning-how-a-vc-firm-works-please-apply/ 2022-06-10T11:12:57+00:00 https://invivo.partners/2022/06/10/job-opportunity-were-seeking-candidates-with-a-strong-scientific-background-to-join-our-internship-opportunity-if-youre-interested-in-learning-how-a-vc-firm-works-please-apply/ 2022-06-10T11:13:25+00:00 https://invivo.partners/2022/06/10/job-opportunity-were-seeking-candidates-with-a-strong-scientific-background-to-join-our-internship-opportunity-if-youre-interested-in-learning-how-a-vc-firm-works-please-apply/ 2022-06-10T11:13:48+00:00 https://invivo.partners/2022/07/04/investing-in-leading-edge/ 2022-07-04T10:47:03+00:00 https://invivo.partners/2022/07/04/investing-in-leading-edge/ 2022-07-04T10:59:34+00:00 https://invivo.partners/2022/07/04/investing-in-leading-edge/ 2022-07-04T11:00:30+00:00 https://invivo.partners/2022/09/20/genfit-adquirira-versantis/ 2022-09-20T09:47:21+00:00 https://invivo.partners/2022/09/20/genfit-adquirira-versantis/ 2022-09-20T09:47:44+00:00 https://invivo.partners/2022/09/20/genfit-adquirira-versantis/ 2022-09-20T09:48:07+00:00 https://invivo.partners/2021/11/22/vifor-pharma-to-acquire-sanifit-to-further-strengthen-late-stage-pipeline-in-nephrology/ 2022-09-20T09:50:51+00:00 https://invivo.partners/2021/11/22/vifor-pharma-to-acquire-sanifit-to-further-strengthen-late-stage-pipeline-in-nephrology/ 2022-09-20T09:56:31+00:00 https://invivo.partners/2021/11/22/vifor-pharma-to-acquire-sanifit-to-further-strengthen-late-stage-pipeline-in-nephrology/ 2022-09-20T09:57:00+00:00 https://invivo.partners/2022/09/20/nos-complace-anunciar-nuestra-segunda-salida-en-menos-de-un-ano-genfit-ha-anunciado-que-adquirira-versantis/ 2022-09-20T09:58:01+00:00 https://invivo.partners/2022/09/20/nos-complace-anunciar-nuestra-segunda-salida-en-menos-de-un-ano-genfit-ha-anunciado-que-adquirira-versantis/ 2022-09-20T09:58:15+00:00 https://invivo.partners/2022/09/20/nos-complace-anunciar-nuestra-segunda-salida-en-menos-de-un-ano-genfit-ha-anunciado-que-adquirira-versantis/ 2022-09-20T09:58:39+00:00 https://invivo.partners/2023/01/17/job-opportunity-our-portfolio-company-telomere-therapeutics-is-seeking-candidates-for-a-project-manager-position/ 2023-01-17T11:03:51+00:00 https://invivo.partners/2023/01/17/job-opportunity-our-portfolio-company-telomere-therapeutics-is-seeking-candidates-for-a-project-manager-position/ 2023-01-17T11:04:32+00:00 https://invivo.partners/2023/01/31/we-are-excited-to-announce-that-claudio-santos-has-joined-us-as-entrepreneur-in-residence-to-support-our-company-creation-activity-in-the-technology-transfer-space/ 2023-02-01T09:45:11+00:00 https://invivo.partners/wp-content/uploads/2023/01/Claudio-Santos_web-scaled-e1675161984144.jpg https://invivo.partners/2023/01/31/we-are-excited-to-announce-that-claudio-santos-has-joined-us-as-entrepreneur-in-residence-to-support-our-company-creation-activity-in-the-technology-transfer-space/ 2023-02-01T09:55:24+00:00 https://invivo.partners/wp-content/uploads/2023/01/Claudio-Santos_web-scaled-e1675161984144.jpg https://invivo.partners/2023/02/09/job-opportunity-investment-analyst/ 2023-02-09T10:35:59+00:00 https://invivo.partners/2023/02/09/job-opportunity-investment-analyst/ 2023-02-09T10:37:38+00:00 https://invivo.partners/2023/02/02/job-opportunity-were-seeking-candidates-to-join-our-internship-program-apply-now/ 2023-02-09T10:49:58+00:00 https://invivo.partners/2023/05/03/portfolio-news-congratulations-to-arthex-biotech-for-successfully-closing-a-e42m-series-b-financing-round-to-advance-their-novel-treatment-for-myotonic-dystrophy-type-1-dm1-we-are-proud-to-have-be/ 2023-05-03T16:22:29+00:00 https://invivo.partners/wp-content/uploads/2023/05/6194be010f431c12d4171e69_arthex-biotech-logo.jpeg https://invivo.partners/2023/06/22/portfolio-news-we-are-excited-to-announce-that-our-portfolio-company-onechain-has-raised-e6-7m-in-a-pre-series-a-funding-round-the-round-involved-the-participation-of-venture-capital-firm-invivo-c/ 2023-06-22T13:52:04+00:00 https://invivo.partners/2019/03/29/invivo-ventures-fcr-nuevo-fondo-de-capital-riesgo-en-el-sector-biomedico/ 2023-09-14T08:03:45+00:00 https://invivo.partners/2019/03/29/invivo-ventures-fcr-nuevo-fondo-de-capital-riesgo-en-el-sector-biomedico/ 2023-09-14T08:04:19+00:00 https://invivo.partners/2020/01/08/the-invivo-ventures-fund-debuts-with-a-round-of-1-5-million-in-arthex-biotech-catalonia-expansion/ 2023-09-14T08:09:07+00:00 https://invivo.partners/2020/01/08/the-invivo-ventures-fund-debuts-with-a-round-of-1-5-million-in-arthex-biotech-catalonia-expansion/ 2023-09-14T08:11:44+00:00 https://invivo.partners/2020/01/08/the-invivo-ventures-fund-debuts-with-a-round-of-1-5-million-in-arthex-biotech-catalonia-expansion/ 2023-09-14T08:11:58+00:00 https://invivo.partners/2020/01/08/invivo-ventures-leads-a-1-5-million-round-la-vanguardia/ 2023-09-14T08:13:26+00:00 https://invivo.partners/2020/01/08/invivo-ventures-leads-a-1-5-million-round-la-vanguardia/ 2023-09-14T08:13:51+00:00 https://invivo.partners/2020/01/08/invivo-ventures-leads-a-1-5-million-round-la-vanguardia/ 2023-09-14T08:14:10+00:00 https://invivo.partners/2020/01/08/invivo-capital-opens-its-biomedical-fund-with-40-million-eurosplantadoce/ 2023-09-14T08:15:36+00:00 https://invivo.partners/2020/01/08/invivo-capital-opens-its-biomedical-fund-with-40-million-eurosplantadoce/ 2023-09-14T08:16:08+00:00 https://invivo.partners/2020/01/08/invivo-capital-opens-its-biomedical-fund-with-40-million-eurosplantadoce/ 2023-09-14T08:16:30+00:00 https://invivo.partners/2019/03/29/invivo-ventures-fcr-nuevo-fondo-de-capital-riesgo-en-el-sector-biomedico/ 2023-09-19T16:31:29+00:00 https://invivo.partners/2023/07/05/job-opportunity-we-are-currently-seeking-a-senior-investment-professional-with-a-strong-scientific-background-and-professional-experience-in-venture-capital-to-join-our-team-apply-now/ 2023-10-04T15:07:22+00:00 https://invivo.partners/wp-content/uploads/2023/02/we-are-hiring_glovo.jpg https://invivo.partners/2023/06/22/portfolio-news-we-are-excited-to-announce-that-our-portfolio-company-onechain-has-raised-e6-7m-in-a-pre-series-a-funding-round-the-round-involved-the-participation-of-venture-capital-firm-invivo-c/ 2023-10-04T15:09:47+00:00 https://invivo.partners/2023/06/22/portfolio-news-we-are-excited-to-announce-that-our-portfolio-company-onechain-has-raised-e6-7m-in-a-pre-series-a-funding-round-the-round-involved-the-participation-of-venture-capital-firm-invivo-c/ 2023-10-04T15:09:47+00:00 https://invivo.partners/2023/05/03/portfolio-news-congratulations-to-arthex-biotech-for-successfully-closing-a-e42m-series-b-financing-round-to-advance-their-novel-treatment-for-myotonic-dystrophy-type-1-dm1-we-are-proud-to-have-be/ 2023-10-04T15:11:36+00:00 https://invivo.partners/wp-content/uploads/2023/05/6194be010f431c12d4171e69_arthex-biotech-logo.jpeg https://invivo.partners/2023/02/09/job-opportunity-investment-analyst/ 2023-10-04T15:13:40+00:00 https://invivo.partners/wp-content/uploads/2023/02/we-are-hiring_glovo.jpg https://invivo.partners/2023/02/02/job-opportunity-were-seeking-candidates-to-join-our-internship-program-apply-now/ 2023-10-04T15:23:44+00:00 https://invivo.partners/wp-content/uploads/2023/02/we-are-hiring_glovo.jpg https://invivo.partners/2023/01/31/we-are-excited-to-announce-that-claudio-santos-has-joined-us-as-entrepreneur-in-residence-to-support-our-company-creation-activity-in-the-technology-transfer-space/ 2023-10-04T15:30:39+00:00 https://invivo.partners/wp-content/uploads/2023/01/Claudio-Santos_web-scaled-e1675161984144.jpg https://invivo.partners/2023/01/17/job-opportunity-our-portfolio-company-telomere-therapeutics-is-seeking-candidates-for-a-project-manager-position/ 2023-10-04T16:42:26+00:00 https://invivo.partners/2023/07/05/job-opportunity-we-are-currently-seeking-a-senior-investment-professional-with-a-strong-scientific-background-and-professional-experience-in-venture-capital-to-join-our-team-apply-now/ 2023-12-12T08:29:42+00:00 https://invivo.partners/2023/02/02/job-opportunity-were-seeking-candidates-to-join-our-internship-program-apply-now/ 2023-12-12T08:30:49+00:00 https://invivo.partners/2023/12/12/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform/ 2023-12-12T10:00:13+00:00 https://invivo.partners/wp-content/uploads/2023/12/esobiotec.jpg https://invivo.partners/2023/12/12/invivo-partners-invierte-en-la-biotecnologica-belga-esobiotec/ 2023-12-12T10:00:40+00:00 https://invivo.partners/2023/12/12/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform/ 2023-12-12T10:01:58+00:00 https://invivo.partners/wp-content/uploads/2023/12/esobiotec.jpg https://invivo.partners/2023/12/12/invivo-partners-invierte-en-la-biotecnologica-belga-esobiotec/ 2023-12-12T10:04:24+00:00 https://invivo.partners/2023/12/12/invivo-inverteix-dos-milions-a-la-belga-esobiotec/ 2023-12-12T10:07:46+00:00 https://invivo.partners/2023/12/12/invivo-inverteix-dos-milions-a-la-belga-esobiotec/ 2023-12-12T10:08:06+00:00 https://invivo.partners/2023/12/12/invivo-inverteix-dos-milions-a-la-belga-esobiotec/ 2023-12-12T10:08:50+00:00 https://invivo.partners/2023/12/12/invivo-partners-invierte-en-la-biotecnologica-belga-esobiotec/ 2023-12-12T14:25:25+00:00 https://invivo.partners/2024/01/08/job-opportunity-internship-program-are-you-willing-to-start-a-career-in-the-venturecapital-space-our-internship-program-is-now-open-apply-now/ 2024-01-08T09:32:50+00:00 https://invivo.partners/2024/01/08/job-opportunity-internship-program-are-you-willing-to-start-a-career-in-the-venturecapital-space-our-internship-program-is-now-open-apply-now/ 2024-01-08T09:33:12+00:00 https://invivo.partners/2024/02/01/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo/ 2024-02-01T16:19:22+00:00 https://invivo.partners/wp-content/uploads/2024/02/IMG_6507-scaled-e1706803656843.jpeg https://invivo.partners/2024/02/01/onechain-immunotherapeutics-anuncia-el-nombramiento-del-dr-stefanos-theoharis-como-nuevo-ceo/ 2024-02-01T16:22:23+00:00 https://invivo.partners/wp-content/uploads/2024/02/IMG_6507-scaled-e1706803656843.jpeg https://invivo.partners/2024/02/28/arthex-biotech-receives-ind-clearance-from-fda-to-initiate-the-phase-i-iia-arthemir-trial-of-atx-01-for-myotonic-dystrophy-type-1-dm1/ 2024-02-28T08:37:59+00:00 https://invivo.partners/wp-content/uploads/2020/02/arthexRecurso-4.png https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/ 2024-03-05T07:43:59+00:00 https://invivo.partners/wp-content/uploads/2024/03/image002-scaled.jpg https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/ 2024-03-05T07:44:31+00:00 https://invivo.partners/wp-content/uploads/2024/03/image002-scaled.jpg https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/ 2024-03-05T07:45:08+00:00 https://invivo.partners/wp-content/uploads/2024/03/image002-scaled.jpg https://invivo.partners/2024/03/19/telum-therapeutics-appoints-dr-subhendu-basu-as-ceo/ 2024-04-17T09:12:12+00:00 https://invivo.partners/wp-content/uploads/2024/04/Michael-Tadros-e1713343076221.jpg https://invivo.partners/2024/03/19/telum-therapeutics-appoints-dr-subhendu-basu-as-ceo/ 2024-04-17T09:22:37+00:00 https://invivo.partners/wp-content/uploads/2024/04/Subhendu-Basu.jpg https://invivo.partners/2024/03/19/telum-therapeutics-appoints-dr-subhendu-basu-as-ceo/ 2024-04-17T09:29:22+00:00 https://invivo.partners/wp-content/uploads/2024/04/Subhendu-Basu.jpg https://invivo.partners/2024/04/17/telomere-therapeutics-appoints-dr-michael-tadros-chief-executive-officer/ 2024-04-17T09:29:50+00:00 https://invivo.partners/wp-content/uploads/2024/04/Michael-Tadros-e1713343076221.jpg https://invivo.partners/2024/04/17/telomere-therapeutics-appoints-dr-michael-tadros-chief-executive-officer/ 2024-04-17T09:30:08+00:00 https://invivo.partners/wp-content/uploads/2024/04/Michael-Tadros-e1713343076221.jpg https://invivo.partners/2024/04/17/telomere-therapeutics-appoints-dr-michael-tadros-chief-executive-officer/ 2024-04-17T09:30:26+00:00 https://invivo.partners/wp-content/uploads/2024/04/Michael-Tadros-e1713343076221.jpg https://invivo.partners/2023/02/02/internship/ 2024-11-11T10:13:21+00:00 https://invivo.partners/2024/01/08/job-opportunity-internship-program-are-you-willing-to-start-a-career-in-the-venturecapital-space-our-internship-program-is-now-open-apply-now/ 2024-11-13T15:03:48+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2023/02/02/internship/ 2024-11-14T16:46:44+00:00 https://invivo.partners/wp-content/uploads/2024/11/Join.jpg https://invivo.partners/2024/11/14/are-you-willing-to-start-a-career-in-the-venture-capital-space-then-keep-reading-this-might-be-of-interest-2/ 2024-11-14T17:09:27+00:00 https://invivo.partners/wp-content/uploads/2024/11/Join.jpg https://invivo.partners/2023/02/02/internship/ 2024-11-14T17:39:29+00:00 https://invivo.partners/wp-content/uploads/2024/11/Join.jpg https://invivo.partners/2024/11/18/job-opportunity-internship-program-are-you-willing-to-start-a-career-in-the-venturecapital-space-our-internship-program-is-now-open-apply-now-2/ 2024-11-18T11:05:00+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2024/11/18/job-opportunity-internship-program-are-you-willing-to-start-a-career-in-the-venturecapital-space-our-internship-program-is-now-open-apply-now-2/ 2024-11-18T11:05:32+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2023/12/12/invivo-ventures-invests-in-esobiotec-to-revolutionize-cancer-cell-therapy-with-cutting-edge-in-vivo-engineering-platform/ 2025-01-08T09:22:46+00:00 https://invivo.partners/wp-content/uploads/2023/12/esobiotec.jpg https://invivo.partners/2025/01/08/invivo-partners-announces-the-first-investment-from-their-new-fund-invivo-ventures-iii-in-neumirna-therapeutics/ 2025-01-08T10:13:35+00:00 https://invivo.partners/wp-content/uploads/2025/01/NEUmiRNA.jpg https://invivo.partners/2025/01/08/invivo-partners-announces-the-first-investment-from-their-new-fund-invivo-ventures-iii-in-neumirna-therapeutics/ 2025-01-08T10:14:04+00:00 https://invivo.partners/wp-content/uploads/2025/01/NEUmiRNA.jpg https://invivo.partners/2025/01/08/invivo-partners-announces-the-first-investment-from-their-new-fund-invivo-ventures-iii-in-neumirna-therapeutics/ 2025-01-08T10:14:27+00:00 https://invivo.partners/wp-content/uploads/2025/01/NEUmiRNA.jpg https://invivo.partners/2025/03/27/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii/ 2025-03-27T10:26:37+00:00 https://invivo.partners/wp-content/uploads/2025/03/luis_serrano_web.jpg https://invivo.partners/wp-content/uploads/2025/03/begona_carreno_web.jpg https://invivo.partners/wp-content/uploads/2025/03/pep_martorell_web.jpg https://invivo.partners/wp-content/uploads/2025/03/theresa_heggie_web.jpg https://invivo.partners/wp-content/uploads/2025/03/tim_lu_web-2.jpg https://invivo.partners/2025/03/27/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii/ 2025-03-27T11:14:37+00:00 https://invivo.partners/wp-content/uploads/2025/03/luis_serrano_web.jpg https://invivo.partners/wp-content/uploads/2025/03/begona_carreno_web.jpg https://invivo.partners/wp-content/uploads/2025/03/pep_martorell_web.jpg https://invivo.partners/wp-content/uploads/2025/03/theresa_heggie_web.jpg https://invivo.partners/wp-content/uploads/2025/03/tim_lu_web-2.jpg https://invivo.partners/2025/03/27/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii/ 2025-03-27T11:15:58+00:00 https://invivo.partners/wp-content/uploads/2025/03/luis_serrano_web.jpg https://invivo.partners/wp-content/uploads/2025/03/begona_carreno_web.jpg https://invivo.partners/wp-content/uploads/2025/03/pep_martorell_web.jpg https://invivo.partners/wp-content/uploads/2025/03/theresa_heggie_web.jpg https://invivo.partners/wp-content/uploads/2025/03/tim_lu_web-2.jpg https://invivo.partners/2025/04/07/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio/ 2025-04-07T07:58:10+00:00 https://invivo.partners/wp-content/uploads/2025/04/Signadori-Bio_200x200.jpg https://invivo.partners/2025/04/07/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio/ 2025-04-07T08:14:30+00:00 https://invivo.partners/wp-content/uploads/2025/04/Signadori-Bio_200x200.jpg https://invivo.partners/2025/04/07/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio/ 2025-04-07T08:19:47+00:00 https://invivo.partners/wp-content/uploads/2025/04/Signadori-Bio_200x200.jpg https://invivo.partners/2024/11/18/job-opportunity-internship-program-are-you-willing-to-start-a-career-in-the-venturecapital-space-our-internship-program-is-now-open-apply-now-2/ 2025-06-11T10:40:20+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2025/06/30/oportunitat-laboral/ 2025-06-30T09:20:41+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2025/06/30/oportunitat-laboral/ 2025-06-30T09:24:06+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2025/06/30/oportunitat-laboral/ 2025-06-30T09:29:40+00:00 https://invivo.partners/wp-content/uploads/2024/11/apply-now.jpg https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/ 2025-09-23T08:34:14+00:00 https://invivo.partners/wp-content/uploads/2025/09/Partners-scaled-e1758559353128.jpg https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/ 2025-09-23T08:34:39+00:00 https://invivo.partners/wp-content/uploads/2025/09/Partners-scaled-e1758559353128.jpg https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/ 2025-09-23T08:35:06+00:00 https://invivo.partners/wp-content/uploads/2025/09/Partners-scaled-e1758559353128.jpg https://invivo.partners/2022/01/26/retina-difficult-indications/ 2025-10-28T16:47:37+00:00 https://invivo.partners/wp-content/uploads/2022/01/RETINA.jpg https://invivo.partners/2022/01/17/difficult-indications/ 2025-10-28T16:48:20+00:00 https://invivo.partners/wp-content/uploads/2022/01/Glioblastoma.jpg https://invivo.partners/2022/01/17/difficult-indications-pancreatic-cancer/ 2025-10-28T16:48:32+00:00 https://invivo.partners/wp-content/uploads/2022/01/DIFFICULT-INDICATIONS-PANCREATIC-CANCER.jpg https://invivo.partners/2021/01/25/cancer-biology-open-problems/ 2025-10-28T16:52:00+00:00 https://invivo.partners/wp-content/uploads/2021/01/CANCER-BIOLOGY-OPEN-PROBLEMS.jpeg https://invivo.partners/2021/01/25/the-art-of-choosing-indications/ 2025-10-28T16:52:19+00:00 https://invivo.partners/wp-content/uploads/2021/01/2021.01.02_THE-ART-OF-CHOOSING-INDICATIONS.jpeg https://invivo.partners/2020/07/01/investments-in-the-times-of-covid19/ 2025-10-28T16:52:26+00:00 https://invivo.partners/wp-content/uploads/2020/07/COVID.jpeg https://invivo.partners/2020/02/21/emerging-fields/ 2025-10-28T16:52:44+00:00 https://invivo.partners/ca/2022/03/18/synthetic-biology-future-directions/ 2025-10-28T16:59:09+00:00 https://invivo.partners/es/2022/03/18/synthetic-biology-future-directions/ 2025-10-28T17:00:35+00:00 https://invivo.partners/2022/01/26/retina-difficult-indications/ 2025-10-28T17:01:58+00:00 https://invivo.partners/wp-content/uploads/2022/01/RETINA.jpg https://invivo.partners/2022/01/26/retina-difficult-indications/ 2025-10-28T17:03:52+00:00 https://invivo.partners/wp-content/uploads/2022/01/RETINA.jpg https://invivo.partners/2022/02/03/launching-a-biotech-startup-2/ 2025-10-28T17:08:54+00:00 https://invivo.partners/wp-content/uploads/2022/02/LAUNCHING-A-BIOTECH-STARTUP.jpg https://invivo.partners/2022/02/03/launching-a-biotech-startup-2/ 2025-10-28T17:18:32+00:00 https://invivo.partners/wp-content/uploads/2021/01/LAUNCHING-A-BIOTECH-STARTUP.jpeg https://invivo.partners/2022/02/03/launching-a-biotech-startup-2/ 2025-10-28T17:25:52+00:00 https://invivo.partners/wp-content/uploads/2022/02/LAUNCHING-A-BIOTECH-STARTUP.jpg https://invivo.partners/2022/01/17/difficult-indications/ 2025-10-28T17:28:16+00:00 https://invivo.partners/wp-content/uploads/2022/01/Glioblastoma.jpg https://invivo.partners/2022/01/17/difficult-indications/ 2025-10-28T17:29:22+00:00 https://invivo.partners/wp-content/uploads/2022/01/Glioblastoma.jpg https://invivo.partners/2022/01/17/difficult-indications-pancreatic-cancer/ 2025-10-28T17:36:15+00:00 https://invivo.partners/wp-content/uploads/2022/01/DIFFICULT-INDICATIONS-PANCREATIC-CANCER.jpg https://invivo.partners/2022/01/17/difficult-indications-pancreatic-cancer/ 2025-10-28T17:37:27+00:00 https://invivo.partners/wp-content/uploads/2022/01/DIFFICULT-INDICATIONS-PANCREATIC-CANCER.jpg https://invivo.partners/2021/01/25/launching-a-biotech-startup/ 2025-10-28T17:39:24+00:00 https://invivo.partners/wp-content/uploads/2022/02/LAUNCHING-A-BIOTECH-STARTUP.jpg https://invivo.partners/2021/01/25/launching-a-biotech-startup/ 2025-10-28T17:44:29+00:00 https://invivo.partners/wp-content/uploads/2021/01/LAUNCHING-A-BIOTECH-STARTUP.jpeg https://invivo.partners/2021/01/25/launching-a-biotech-startup/ 2025-10-28T17:44:59+00:00 https://invivo.partners/wp-content/uploads/2021/01/LAUNCHING-A-BIOTECH-STARTUP.jpeg https://invivo.partners/2021/01/25/oncology-future-directions/ 2025-10-28T17:47:03+00:00 https://invivo.partners/wp-content/uploads/2021/01/ONCOLOGY-FUTURE-DIRECTIONS-scaled.jpeg https://invivo.partners/2021/01/25/oncology-future-directions/ 2025-10-28T17:47:03+00:00 https://invivo.partners/wp-content/uploads/2021/01/ONCOLOGY-FUTURE-DIRECTIONS.jpeg https://invivo.partners/2021/01/25/oncology-future-directions/ 2025-10-28T17:47:04+00:00 https://invivo.partners/wp-content/uploads/2021/01/ONCOLOGY-FUTURE-DIRECTIONS.jpeg https://invivo.partners/2021/01/25/cancer-biology-open-problems/ 2025-10-28T17:48:22+00:00 https://invivo.partners/wp-content/uploads/2021/01/CANCER-BIOLOGY-OPEN-PROBLEMS-scaled.jpeg https://invivo.partners/2021/01/25/rna-therapies/ 2025-10-28T17:49:20+00:00 https://invivo.partners/wp-content/uploads/2021/01/RNA-THERAPIES-scaled.jpeg https://invivo.partners/2021/01/25/rna-therapies/ 2025-10-28T17:49:20+00:00 https://invivo.partners/wp-content/uploads/2021/01/RNA-THERAPIES.jpeg https://invivo.partners/2021/01/25/rna-therapies/ 2025-10-28T17:49:21+00:00 https://invivo.partners/wp-content/uploads/2021/01/RNA-THERAPIES.jpeg https://invivo.partners/2021/01/25/covid19-vaccines-landscape/ 2025-10-28T17:50:08+00:00 https://invivo.partners/wp-content/uploads/2021/01/COVID19-VACCINES-LANDSCAPE.jpeg https://invivo.partners/2021/01/25/covid19-vaccines-landscape/ 2025-10-28T17:50:09+00:00 https://invivo.partners/wp-content/uploads/2021/01/COVID19-VACCINES-LANDSCAPE.jpeg https://invivo.partners/2021/01/25/covid19-vaccines-landscape/ 2025-10-28T17:50:09+00:00 https://invivo.partners/wp-content/uploads/2021/01/COVID19-VACCINES-LANDSCAPE.jpeg https://invivo.partners/2021/01/25/the-art-of-choosing-indications/ 2025-10-28T17:50:54+00:00 https://invivo.partners/wp-content/uploads/2021/01/2021.01.02_THE-ART-OF-CHOOSING-INDICATIONS.jpeg https://invivo.partners/2020/07/01/investments-in-the-times-of-covid19/ 2025-10-28T17:51:40+00:00 https://invivo.partners/wp-content/uploads/2020/07/COVID.jpeg https://invivo.partners/2020/05/13/orphan-drugs/ 2025-10-28T17:52:28+00:00 https://invivo.partners/wp-content/uploads/2020/05/orphan-drugs.jpg https://invivo.partners/2020/05/13/orphan-drugs/ 2025-10-28T17:52:28+00:00 https://invivo.partners/wp-content/uploads/2020/05/orphan-drugs.jpg https://invivo.partners/2020/05/13/orphan-drugs/ 2025-10-28T17:52:28+00:00 https://invivo.partners/wp-content/uploads/2020/05/orphan-drugs.jpg https://invivo.partners/2020/04/20/sars-cov-2/ 2025-10-28T17:54:36+00:00 https://invivo.partners/wp-content/uploads/2020/04/2020.04.20_SARS-CoV-2.jpg https://invivo.partners/2020/04/20/sars-cov-2/ 2025-10-28T17:55:03+00:00 https://invivo.partners/wp-content/uploads/2020/04/2020.04.20_SARS-CoV-2.jpg https://invivo.partners/2020/02/21/emerging-fields/ 2025-10-28T17:57:37+00:00 https://invivo.partners/wp-content/uploads/2020/02/b3Recurso-2.png https://invivo.partners/2020/02/06/creative-self-portrait/ 2025-10-28T18:02:47+00:00 https://invivo.partners/wp-content/uploads/2021/01/RNA-THERAPIES.jpeg https://invivo.partners/2020/02/06/creative-self-portrait/ 2025-10-28T18:02:47+00:00 https://invivo.partners/wp-content/uploads/2021/01/RNA-THERAPIES.jpeg https://invivo.partners/2020/02/06/creative-self-portrait/ 2025-10-28T18:02:51+00:00 https://invivo.partners/wp-content/uploads/2020/02/bloigRecurso-5.png https://invivo.partners/2022/10/18/synthetic-biology-future-directions/ 2025-10-28T18:14:34+00:00 https://invivo.partners/wp-content/uploads/2022/03/SYNTHETIC-BIOLOGY-FUTURE-DIRECTIONS.jpg https://invivo.partners/2022/10/18/synthetic-biology-future-directions/ 2025-10-28T18:14:35+00:00 https://invivo.partners/wp-content/uploads/2022/03/SYNTHETIC-BIOLOGY-FUTURE-DIRECTIONS.jpg https://invivo.partners/2022/10/18/synthetic-biology-future-directions/ 2025-10-28T18:14:35+00:00 https://invivo.partners/wp-content/uploads/2022/03/SYNTHETIC-BIOLOGY-FUTURE-DIRECTIONS.jpg https://invivo.partners/2021/01/25/cancer-biology-open-problems/ 2025-10-28T18:32:33+00:00 https://invivo.partners/wp-content/uploads/2021/01/CANCER-BIOLOGY-OPEN-PROBLEMS.jpeg https://invivo.partners/2020/07/01/investments-in-the-times-of-covid19/ 2025-10-28T18:32:48+00:00 https://invivo.partners/wp-content/uploads/2020/07/COVID.jpeg https://invivo.partners/2020/04/20/sars-cov-2/ 2025-10-28T18:32:54+00:00 https://invivo.partners/wp-content/uploads/2020/04/2020.04.20_SARS-CoV-2.jpg https://invivo.partners/2020/02/21/emerging-fields/ 2025-10-28T18:33:00+00:00 https://invivo.partners/2021/01/25/the-art-of-choosing-indications/ 2025-10-28T18:33:15+00:00 https://invivo.partners/wp-content/uploads/2021/01/2021.01.02_THE-ART-OF-CHOOSING-INDICATIONS.jpeg https://invivo.partners/2025/10/29/esgct/ 2025-10-29T09:22:17+00:00 https://invivo.partners/wp-content/uploads/2025/10/0f1a36_77ed03efe8ab48caaafb7438d2d9e178mv2-e1761729100159.avif https://invivo.partners/ca/2025/10/27/esgct/ 2025-10-29T09:23:20+00:00 https://invivo.partners/wp-content/uploads/2025/10/0f1a36_77ed03efe8ab48caaafb7438d2d9e178mv2-e1761729100159.avif https://invivo.partners/es/2025/10/27/esgct/ 2025-10-29T09:23:51+00:00 https://invivo.partners/2025/10/29/josep-maria-martorell-estamos-en-el-momento-mas-caliente-de-la-investigacion-cientifica-en-la-historia/ 2025-10-29T16:43:44+00:00 https://invivo.partners/2025/10/29/josep-maria-martorell-estamos-en-el-momento-mas-caliente-de-la-investigacion-cientifica-en-la-historia/ 2025-10-29T16:45:44+00:00 https://invivo.partners/2025/10/29/josep-maria-martorell-estamos-en-el-momento-mas-caliente-de-la-investigacion-cientifica-en-la-historia/ 2025-10-29T16:48:31+00:00